ALPAU — Alpha Healthcare Acquisition III Share Price
Last trade - 00:00- $192.75m
- $192.73m
- 51
- 43
- 31
- 35
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 1.24 | ||
| Price to Tang. Book | 1.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | n/a | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -1.2% | ||
| Return on Equity | 0.86% | ||
| Operating Margin | n/a | ||
Financial Summary
| Year End 31st Dec | Unit | 2018 | 2019 | 2020 | 2021 | 2022 | 2023E | 2024E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | $m | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
Carmell Therapeutics Corporation is a regenerative medicine platform company. The Company is engaged in the development of allogeneic plasma-based bioactive material (PBM) that is designed to boost innate regenerative pathways across a variety of bone and soft tissue indications. The PBM technology is licensed from Carnegie Mellon University and claims the ability to plasticize whole plasma and cross link with genipin, a derivative of the gardenia plant, to provide a controlled degradation profile in vivo. The Company’s lead product, CT-101 Bone Healing Accelerant (BHA), a biologic, is designated by the United States Food and Drug Administration (FDA) as a combination product, containing the Company’s core technology of PBM plus B Tri-Calcium Phosphate (B-TCP) an already approved medical device. The Company has FDA clearance for a Phase II-stage clinical trial designed to study accelerated healing and reduced infections in open tibia (shinbone) fractures with intramedullary rodding.
Directors
- Last Annual
- December 31st, 2022
- Last Interim
- March 31st, 2023
- Incorporated
- January 21st, 2021
- Public Since
- July 29th, 2021
- No. of Shareholders
- 2
- No. of Employees
- 10
- Sector
- Holding Companies
- Industry
- Financials
- Exchange
- NASDAQ Capital Market
- Shares in Issue
- 19,769,011
- Address
- 2403 Sidney Street, Suite 300, PITTSBURGH, 15203
- Web
- https://www.carmellrx.com/
- Phone
- +1 4128948248
- Auditors
- Marcum LLP
Similar to ALPAU
10X Capital Venture Acquisition II
NASDAQ Capital Market
10X Capital Venture Acquisition II
NASDAQ Capital Market
1Sharpe Acquisition
NASDAQ Capital Market
26 Capital Acquisition
NASDAQ Capital Market
26 Capital Acquisition
NASDAQ Capital Market
FAQ
As of Today at 01:02 UTC, shares in Alpha Healthcare Acquisition III are trading at $9.75. This share price information is delayed by 15 minutes.
Shares in Alpha Healthcare Acquisition III last closed at $9.75 and the price had moved by -0.71% over the past 365 days. In terms of relative price strength the Alpha Healthcare Acquisition III share price has underperformed the S&P500 Index by -15.9% over the past year.
There is no consensus recommendation for this security.
Find out moreAlpha Healthcare Acquisition III does not currently pay a dividend.
Alpha Healthcare Acquisition III does not currently pay a dividend.
Alpha Healthcare Acquisition III does not currently pay a dividend.
To buy shares in Alpha Healthcare Acquisition III you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
As of the previous close price of $9.75, shares in Alpha Healthcare Acquisition III had a market capitalisation of $192.75m.
Here are the trading details for Alpha Healthcare Acquisition III:
- Country of listing: United States
- Exchange: NAQ
- Ticker Symbol: ALPAU
Based on an overall assessment of its quality, value and momentum Alpha Healthcare Acquisition III is currently classified as a Neutral. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
We could not find analyst target price data for this security.
Find out moreAn important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like Alpha Healthcare Acquisition III. Over the past six months, its share price has underperformed the S&P500 Index by -15.61%.
As of the last closing price of $9.75, shares in Alpha Healthcare Acquisition III were trading -1.81% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
The Alpha Healthcare Acquisition III PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at $9.75.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
We do not have data on Alpha Healthcare Acquisition III's directors